Unlock stock picks and a broker-level newsfeed that powers Wall Street.
Taiwan - Delayed Quote TWD

OK Biotech Co., Ltd. (4155.TW)

Compare
19.00
-0.05
(-0.26%)
At close: April 2 at 1:30:22 PM GMT+8
Loading Chart for 4155.TW
  • Previous Close 19.05
  • Open 19.00
  • Bid 18.95 x --
  • Ask 19.00 x --
  • Day's Range 18.85 - 19.05
  • 52 Week Range 18.60 - 28.20
  • Volume 163,277
  • Avg. Volume 164,442
  • Market Cap (intraday) 2.794B
  • Beta (5Y Monthly) 0.15
  • PE Ratio (TTM) 29.69
  • EPS (TTM) 0.64
  • Earnings Date Apr 30, 2025 - May 5, 2025
  • Forward Dividend & Yield 0.30 (1.58%)
  • Ex-Dividend Date Sep 5, 2024
  • 1y Target Est --

OK Biotech Co., Ltd. develops, manufactures, markets, and sells blood glucose monitoring devices and related homecare medical products in Taiwan and internationally. It also provides glucometers and blood glucose test strips; nebulizer, portable nebulizer, mesh nebulizer, and test strips; and personal sound amplifiers. OK Biotech Co., Ltd. was founded in 2006 and is headquartered in Hsinchu City, Taiwan.

www.okbiotech.com

--

Full Time Employees

December 31

Fiscal Year Ends

Recent News: 4155.TW

View More

Performance Overview: 4155.TW

Trailing total returns as of 4/2/2025, which may include dividends or other distributions. Benchmark is TSEC CAPITALIZATION WEIGHTED ST (^TWII) .

YTD Return

4155.TW
7.09%
TSEC CAPITALIZATION WEIGHTED ST (^TWII)
7.54%

1-Year Return

4155.TW
20.48%
TSEC CAPITALIZATION WEIGHTED ST (^TWII)
4.06%

3-Year Return

4155.TW
4.64%
TSEC CAPITALIZATION WEIGHTED ST (^TWII)
20.84%

5-Year Return

4155.TW
4.76%
TSEC CAPITALIZATION WEIGHTED ST (^TWII)
120.40%

Compare To: 4155.TW

Select to analyze similar companies using key performance metrics; select up to 4 stocks.

Statistics: 4155.TW

View More

Valuation Measures

Annual
As of 4/2/2025
  • Market Cap

    2.79B

  • Enterprise Value

    3.28B

  • Trailing P/E

    29.69

  • Forward P/E

    --

  • PEG Ratio (5yr expected)

    --

  • Price/Sales (ttm)

    1.67

  • Price/Book (mrq)

    1.12

  • Enterprise Value/Revenue

    1.97

  • Enterprise Value/EBITDA

    15.96

Financial Highlights

Profitability and Income Statement

  • Profit Margin

    5.63%

  • Return on Assets (ttm)

    1.06%

  • Return on Equity (ttm)

    4.28%

  • Revenue (ttm)

    1.67B

  • Net Income Avi to Common (ttm)

    93.97M

  • Diluted EPS (ttm)

    0.64

Balance Sheet and Cash Flow

  • Total Cash (mrq)

    290.5M

  • Total Debt/Equity (mrq)

    28.05%

  • Levered Free Cash Flow (ttm)

    -443.16M

Research Analysis: 4155.TW

View More

Company Insights: 4155.TW

Research Reports: 4155.TW

View More

People Also Watch